Long-Term Follow-Up from the Phase 1/2 MajesTEC-1 trial of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

home / between-the-lines / long-term-follow-up-from-the-phase-1-2-majestec-1-trial-of-teclistamab

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, review recent data from the MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma and have a discussion on evolving therapeutic practices.